Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China · Delayed Price · Currency is CNY 20.55
-0.47 (-2.24%)
At close: Nov 13, 2026
SHE:301089 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 428.05 | 376.82 | 421.65 | 831.98 | 777.81 | 500.26 |
Other Revenue | 1.52 | 1.52 | 0.04 | 3.53 | 6.91 | 2.22 |
| 429.58 | 378.34 | 421.69 | 835.51 | 784.72 | 502.48 | |
Revenue Growth | 16.89% | -10.28% | -49.53% | 6.47% | 56.17% | -4.82% |
Cost of Revenue | 359.2 | 296.95 | 309.52 | 365.37 | 329.64 | 314.12 |
Gross Profit | 70.38 | 81.39 | 112.17 | 470.14 | 455.08 | 188.36 |
Selling, General & Admin | 87.9 | 103.05 | 101.32 | 101.65 | 107.5 | 75.61 |
Research & Development | 43.04 | 42.68 | 40.05 | 51.25 | 31.02 | 20.97 |
Other Operating Expenses | 8.82 | 8.14 | 7.87 | 13.02 | 11.77 | 6.79 |
Operating Expenses | 152.9 | 166.1 | 153.32 | 170.4 | 147.28 | 104.45 |
Operating Income | -82.52 | -84.7 | -41.15 | 299.74 | 307.8 | 83.92 |
Interest Expense | -0.03 | -0.15 | -0.05 | -0.34 | -3.38 | -9.13 |
Interest & Investment Income | 2.91 | 5.02 | 3.31 | 9.86 | 10.64 | 2.41 |
Currency Exchange Gain (Loss) | -0.6 | -0.6 | 1.03 | 0.68 | 1.5 | -1.19 |
Other Non Operating Income (Expenses) | -0.45 | -0.18 | -0.21 | -0.27 | 1.83 | -1.82 |
EBT Excluding Unusual Items | -80.7 | -80.62 | -37.07 | 309.66 | 318.39 | 74.19 |
Gain (Loss) on Sale of Investments | 0.09 | 0.15 | 0.88 | 0.55 | 0.16 | 0.62 |
Gain (Loss) on Sale of Assets | 0.37 | - | -0.01 | - | 0.03 | - |
Asset Writedown | -5.96 | -0.42 | -1.42 | -4.22 | -1.03 | -0.3 |
Other Unusual Items | 6.92 | 8.5 | 9.88 | 10.54 | 7.73 | 3.53 |
Pretax Income | -79.28 | -72.39 | -27.73 | 316.53 | 325.27 | 78.04 |
Income Tax Expense | 1.18 | -2.72 | -7.85 | 73.46 | 38.73 | 12.33 |
Earnings From Continuing Operations | -80.46 | -69.66 | -19.88 | 243.07 | 286.54 | 65.71 |
Net Income | -80.46 | -69.66 | -19.88 | 243.07 | 286.54 | 65.71 |
Net Income to Common | -80.46 | -69.66 | -19.88 | 243.07 | 286.54 | 65.71 |
Net Income Growth | - | - | - | -15.17% | 336.05% | -41.75% |
Shares Outstanding (Basic) | 128 | 127 | 124 | 126 | 126 | 100 |
Shares Outstanding (Diluted) | 128 | 127 | 124 | 126 | 126 | 100 |
Shares Change | 7.88% | 1.91% | -1.32% | -0.22% | 26.78% | 5.03% |
EPS (Basic) | -0.63 | -0.55 | -0.16 | 1.93 | 2.27 | 0.66 |
EPS (Diluted) | -0.63 | -0.55 | -0.16 | 1.93 | 2.27 | 0.66 |
EPS Growth | - | - | - | -14.98% | 243.94% | -44.54% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -64.83 | -70.64 | 18.76 | -158.27 | 120.52 | -54.53 |
Free Cash Flow Per Share | -0.51 | -0.56 | 0.15 | -1.26 | 0.95 | -0.55 |
Dividend Per Share | - | - | - | 0.250 | 0.400 | 0.100 |
Dividend Growth | - | - | - | -37.50% | 300.00% | - |
Gross Margin | 16.38% | 21.51% | 26.60% | 56.27% | 57.99% | 37.49% |
Operating Margin | -19.21% | -22.39% | -9.76% | 35.88% | 39.22% | 16.70% |
Profit Margin | -18.73% | -18.41% | -4.71% | 29.09% | 36.51% | 13.08% |
Free Cash Flow Margin | -15.09% | -18.67% | 4.45% | -18.94% | 15.36% | -10.85% |
EBITDA | -3.76 | -19.39 | 6.24 | 346.33 | 348.32 | 114.84 |
EBITDA Margin | -0.88% | -5.12% | 1.48% | 41.45% | 44.39% | 22.85% |
D&A For EBITDA | 78.76 | 65.31 | 47.39 | 46.59 | 40.52 | 30.92 |
EBIT | -82.52 | -84.7 | -41.15 | 299.74 | 307.8 | 83.92 |
EBIT Margin | -19.21% | -22.39% | -9.76% | 35.88% | 39.22% | 16.70% |
Effective Tax Rate | - | - | - | 23.21% | 11.91% | 15.80% |
Revenue as Reported | 106.79 | 378.34 | 421.69 | 835.51 | 784.72 | 502.48 |
Advertising Expenses | - | 1.99 | 4.71 | 1.81 | 1.15 | 0.66 |